In addition, the inhibition of lysine-specific demethylase 1 (LSD1) with compounds such as bomedemstat has been reported to enhance MHC-I-mediated antigen presentation, sensitizing SCLC tumors to PD-1/PD-L1 inhibitors [11, 12]. This evidence concerns the gene CD274 and small cell lung carcinoma.